Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
about
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataReduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Hepatic, gastric and intestinal first-pass effects of vitexin-2''-O-rhamnoside in rats by ultra-high-performance liquid chromatography.Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.Numerical analysis of time dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting.Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug InteractionsA mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineIntracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simulation.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Role of Hepatic Drug Transporters in Drug Development.Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics
P2860
Q27022933-27DC9913-6DDF-48E3-90ED-AA6C92B85959Q28088352-257C2BC3-19E8-4CC1-8C6E-D91DC54247C8Q30666721-ED8B5220-FEF8-4AA8-85A6-629BC98BDDD2Q30776360-C550790A-8762-4A3C-995E-3D924CFEA816Q33581531-BE1A8EE1-D2D7-4320-9ADC-8261169270E6Q34571360-AFF401C3-082D-4A6F-83DE-8C5F1CD574A6Q35648771-94F0AFFF-DA12-4349-A158-BA5D80C02321Q36036200-B9EA2C4D-8F20-4B9E-952D-8728EADDD0B5Q36413309-30F5F0AA-D191-4177-AC15-0A3333EA4FC2Q37145705-8BD7F665-D568-49E7-9FFE-054E5795F6EBQ37470663-15A2B30A-15DE-498B-868C-F4BAAA06AB51Q37504548-F288F92B-58F9-4909-AB8B-0E5CE3170632Q38214334-F798F64C-4B58-470C-814F-7FF6781D6160Q38233298-591376A7-1915-4D2B-9DAD-EC8EFD7B2FACQ38748975-E2CED9C3-7C9C-48C6-9D4E-024AA498D613Q38793280-DADA3EFA-CFA7-45B2-AC2A-EF72A1A62D83Q39773424-B7DF62D1-C39B-49DA-B8E8-1CCC7ECE6EF3Q40260228-FE891060-9681-4427-A957-5BDB7829B76CQ41368460-76087512-7642-4C92-A7C7-86C80CB08FBBQ41671785-1505AD11-3A96-4858-8D29-B998832344C9Q45243894-9331AD58-0F00-4ED6-A514-9847C9CFA0EEQ47305834-A74FF4DD-25F3-456D-AF84-82122DDFA719Q47592224-BA314478-A366-4C45-B714-A7ED0A220CA9Q51659233-8D35C325-D650-45AD-9B9E-4BD9DACFE1A5Q54053216-1D219400-5C65-47AF-AF55-FC2CA202B24BQ55046512-A37F1191-6B06-4ADC-A8B7-2AFFAEF28BEEQ58712139-E10FC430-487D-4C23-998A-235C0B402E85
P2860
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@en
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@nl
type
label
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@en
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@nl
prefLabel
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@en
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@nl
P2093
P2860
P1476
Cyclosporine inhibition of hep ...... ug-drug interaction potential.
@en
P2093
Catherine M Cartwright
J Brian Houston
Kathryn E Kenworthy
Malcolm Rowland
Michael Gertz
Michael J Hobbs
P2860
P304
P356
10.1007/S11095-012-0918-Y
P577
2012-11-22T00:00:00Z